Coya Therapeutics 获得加拿大卫生部的临床试验申请(CTA)批准,可以推进 Coya 302 Alstars 试验,以治疗肌萎缩侧索硬化症(ALS)。
Coya Therapeutics 获得加拿大卫生部的临床试验申请(CTA)批准,可以推进 Coya 302 Alstars 试验,以治疗肌萎缩侧索硬化症(ALS)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.